JP2004509895A5 - - Google Patents

Download PDF

Info

Publication number
JP2004509895A5
JP2004509895A5 JP2002529112A JP2002529112A JP2004509895A5 JP 2004509895 A5 JP2004509895 A5 JP 2004509895A5 JP 2002529112 A JP2002529112 A JP 2002529112A JP 2002529112 A JP2002529112 A JP 2002529112A JP 2004509895 A5 JP2004509895 A5 JP 2004509895A5
Authority
JP
Japan
Prior art keywords
epoxy
isoindole
methyl
dioxo
octahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002529112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509895A (ja
JP4966477B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/019655 external-priority patent/WO2002024702A1/en
Publication of JP2004509895A publication Critical patent/JP2004509895A/ja
Publication of JP2004509895A5 publication Critical patent/JP2004509895A5/ja
Application granted granted Critical
Publication of JP4966477B2 publication Critical patent/JP4966477B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002529112A 2000-09-19 2001-06-20 核ホルモン・レセプタ機能のモジュレーターである、縮合複素環式スクシンイミド化合物およびその類縁体 Expired - Fee Related JP4966477B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23351900P 2000-09-19 2000-09-19
US60/233,519 2000-09-19
US28443801P 2001-04-18 2001-04-18
US28473001P 2001-04-18 2001-04-18
US60/284,438 2001-04-18
US60/284,730 2001-04-18
PCT/US2001/019655 WO2002024702A1 (en) 2000-09-19 2001-06-20 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Publications (3)

Publication Number Publication Date
JP2004509895A JP2004509895A (ja) 2004-04-02
JP2004509895A5 true JP2004509895A5 (enExample) 2008-08-21
JP4966477B2 JP4966477B2 (ja) 2012-07-04

Family

ID=27398441

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002529112A Expired - Fee Related JP4966477B2 (ja) 2000-09-19 2001-06-20 核ホルモン・レセプタ機能のモジュレーターである、縮合複素環式スクシンイミド化合物およびその類縁体

Country Status (36)

Country Link
US (1) US20040176324A1 (enExample)
EP (1) EP1319007B9 (enExample)
JP (1) JP4966477B2 (enExample)
KR (1) KR100765670B1 (enExample)
CN (2) CN1307181C (enExample)
AR (1) AR035340A1 (enExample)
AT (1) ATE318822T1 (enExample)
AU (2) AU6994301A (enExample)
BG (1) BG107675A (enExample)
BR (1) BR0113980A (enExample)
CA (1) CA2423071A1 (enExample)
CZ (1) CZ2003780A3 (enExample)
DE (1) DE60117551T2 (enExample)
DK (1) DK1319007T3 (enExample)
EE (1) EE200300108A (enExample)
ES (1) ES2260244T3 (enExample)
GE (1) GEP20074144B (enExample)
HK (1) HK1054230B (enExample)
HR (1) HRP20030305B9 (enExample)
HU (1) HUP0400455A3 (enExample)
IL (1) IL155019A0 (enExample)
IS (1) IS6750A (enExample)
MX (1) MXPA03002412A (enExample)
MY (1) MY138531A (enExample)
NO (1) NO329931B1 (enExample)
NZ (1) NZ524803A (enExample)
PE (1) PE20020729A1 (enExample)
PL (1) PL361707A1 (enExample)
PT (1) PT1319007E (enExample)
SK (1) SK4982003A3 (enExample)
TW (1) TWI305208B (enExample)
UA (1) UA78686C2 (enExample)
UY (1) UY26808A1 (enExample)
WO (1) WO2002024702A1 (enExample)
YU (1) YU20003A (enExample)
ZA (1) ZA200302963B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
HUP0303172A3 (en) * 2000-06-28 2006-05-29 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, desing and use
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7087636B2 (en) 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
TWI263640B (en) * 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
NZ538713A (en) 2002-08-12 2007-01-26 Takeda Chemical Industries Ltd Fused benzene derivative and use
WO2004110978A2 (en) * 2003-06-10 2004-12-23 Smithkline Beecham Corporation 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors
US7417040B2 (en) * 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
WO2007015567A1 (ja) * 2005-08-01 2007-02-08 Takeda Pharmaceutical Company Limited 環状アミン化合物
WO2008007664A1 (en) * 2006-07-11 2008-01-17 Takeda Pharmaceutical Company Limited Bicyclic heterocyclic compound and use thereof
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US20120135997A1 (en) 2009-07-17 2012-05-31 Shionogi & Co., Ltd. Pharmaceutical composition comprising a lactam or benzenesulfonamide compound
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2019241469A1 (en) 2018-06-14 2019-12-19 The Scripps Research Institute Nonmuscle myosin ii inhibitors for substance use relapse
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US20250270205A1 (en) * 2020-09-19 2025-08-28 Augusta University Research Institute, Inc. Compositions and methods for inhibiting trem-1
CN115340483A (zh) * 2022-08-31 2022-11-15 南京吉星生物技术开发有限公司 一种萘基吡咯啉二酮化合物及其制备方法与它的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3261845A (en) * 1964-07-14 1966-07-19 Dow Chemical Co N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide
JPS5046697A (enExample) * 1973-08-20 1975-04-25
US5539126A (en) * 1994-04-20 1996-07-23 Bristol-Myers Squibb Company Method for preparing homochiral maleimide intermediates, via silylation techniques
AU717251B2 (en) * 1994-12-22 2000-03-23 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
BR9710988A (pt) * 1996-06-27 2002-01-15 Ligand Pharm Inc Método e compostos moduladores receptores de androgênio
WO1998049555A1 (en) * 1997-04-29 1998-11-05 The Salk Institute For Biological Studies Methods for identifying ligands for nuclear hormone receptors
US7101681B1 (en) * 1997-11-21 2006-09-05 Amgen, Inc. Nuclear hormone receptor drug screens
EP1214325B1 (en) * 1999-09-10 2005-11-09 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
HUP0303172A3 (en) * 2000-06-28 2006-05-29 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, desing and use

Similar Documents

Publication Publication Date Title
KR100765670B1 (ko) 융합된 헤테로시클릭 숙신이미드 화합물 및 그의 유사체,핵 호르몬 수용체 기능의 조절제
JP2021011495A5 (enExample)
ES2534392T3 (es) Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso
JP2022534424A5 (enExample)
AR040971A1 (es) Compuestos pirimido que tienen actividad antiproliferativa
CA2651363A1 (en) Triazolopyrazine derivatives useful as anti-cancer agents
JP2008526999A5 (enExample)
JP2007538092A5 (enExample)
YU35603A (sh) Derivati benzodiazepina kao modulatori gaba a receptora
CA2737999A1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
AU2003215618B2 (en) Use of epothilones in the treatment of brain diseases associated with proliferative processes
JP2003528096A5 (enExample)
CN1774253A (zh) 用环氧丙酯酮衍生物治疗顽固性肿瘤
MXPA06000191A (es) Combinacion de los inhibidores de src cinasa y agentes quimioterapeuticos para el tratamiento de enfermedades proliferativas.
RU2008110917A (ru) ПРОИЗВОДНЫЕ 7-(2-АМИНО-1-ГИДРОКСИ-ЭТИЛ)-4-ГИДРОКСИБЕНЗОТИАЗОЛ-2(3Н)-ОНА В КАЧЕСТВЕ АГОНИСТОВ β2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ
JP2006512366A5 (enExample)
JP2005521676A5 (enExample)
JP2006516626A5 (enExample)
CN120379992A (zh) 蛋白酪氨酸磷酸酶抑制剂、组合物及使用方法
RU2009101299A (ru) Трициклическое соединение и его фармацевтическое применение
JP2024542949A5 (enExample)
RU2378278C2 (ru) ЗАМЕЩЕННЫЕ 3-СУЛЬФОНИЛ-[1,2,3]ТРИАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ
RU2007116987A (ru) Новые соединения
RU2009128968A (ru) Производные изосорбидмононитрата для лечения повышенной внутриглазной гипертензии
JP2009514801A5 (enExample)